For a patient who presented with atrial fibrillation with rapid ventricular response and is now in normal sinus tachycardia, which discharge medications are appropriate?

Discharge Medications for Atrial Fibrillation Now in Normal Sinus Rhythm

Discharge this patient on anticoagulation (based on CHA₂DS₂-VASc score) and consider a beta-blocker for rhythm maintenance, while avoiding antiarrhythmic drugs unless there is recurrent symptomatic AF. Since the patient has spontaneously converted to sinus rhythm, the immediate priority is stroke prevention rather than rhythm control.

Critical Decision Points

1. Anticoagulation (Highest Priority)

Start oral anticoagulation if CHA₂DS₂-VASc score ≥2 in men or ≥3 in women 1, 2. This is a Class I recommendation regardless of whether the patient is currently in sinus rhythm, because:

• The stroke risk persists even after conversion to sinus rhythm
• Anticoagulation should be continued long-term based on thromboembolic risk factors, not rhythm status 2

Preferred agents:

• Direct oral anticoagulants (DOACs) are first-line: apixaban, rivaroxaban, or dabigatran 3
• Warfarin (INR 2.0-3.0) if DOACs are contraindicated 1

For low-risk patients (CHA₂DS₂-VASc score 0 in men, 1 in women): Anticoagulation is not recommended 1

2. Rate Control Medication

Prescribe a beta-blocker as the primary discharge medication 4. This serves dual purposes:

• Prevents rapid ventricular response if AF recurs
• May help maintain sinus rhythm in some patients 5

Alternative if beta-blocker contraindicated:

• Nondihydropyridine calcium channel blocker (diltiazem or verapamil) 4
• These are equally effective for rate control 6

Avoid digoxin monotherapy for paroxysmal AF—it's ineffective for preventing rapid rates during recurrence 7, 1

3. Antiarrhythmic Drugs (Rhythm Control)

Do NOT routinely discharge on antiarrhythmic drugs unless specific criteria are met 5:

Consider antiarrhythmic therapy ONLY if:

• Patient has recurrent symptomatic paroxysmal AF despite rate control
• Patient has no structural heart disease (for flecainide/propafenone) 5
• Patient has heart failure or structural disease (consider amiodarone) 8

Specific agents by cardiac substrate:

For patients WITHOUT structural heart disease:

• Flecainide or propafenone can be initiated outpatient if patient is in sinus rhythm 5
• Must co-prescribe beta-blocker or calcium channel blocker to prevent 1:1 atrial flutter conduction 5

For patients WITH heart failure or structural disease:

• Amiodarone is reasonable 8
• Avoid Class IC drugs (flecainide, propafenone) 5

For patients with coronary disease:

• Class IC drugs are contraindicated 5
• Consider amiodarone or sotalol

4. Common Pitfalls to Avoid

Do not discharge on antiarrhythmic drugs "just in case":

• Infrequent, well-tolerated AF recurrence is an acceptable outcome 5
• Antiarrhythmics have significant proarrhythmic and side effect risks
• Rate control strategy is often preferred, especially in elderly 8

Do not forget anticoagulation:

• Even though patient is in sinus rhythm now, stroke risk remains elevated 5
• Anticoagulation decision is based on CHA₂DS₂-VASc score, not current rhythm 2

Do not use sotalol or dofetilide without:

• Baseline QTc measurement
• Renal function assessment
• Inpatient monitoring for initiation 5

Practical Discharge Algorithm

1. Calculate CHA₂DS₂-VASc score → Start DOAC if ≥2 (men) or ≥3 (women)
2. Prescribe beta-blocker (or calcium channel blocker if contraindicated)
3. Assess for structural heart disease:
   • None present → No antiarrhythmic needed; consider flecainide/propafenone only if recurrent symptomatic AF
   • Present → No antiarrhythmic needed unless recurrent symptomatic AF, then consider amiodarone
4. Arrange cardiology follow-up within 2-4 weeks for rhythm monitoring and medication adjustment

Special Considerations

If patient has heart failure:

• Beta-blocker is Class I recommendation 4, 8
• Digoxin can be added for additional rate control 4
• Avoid nondihydropyridine calcium channel blockers in decompensated HF 4

If patient has hyperthyroidism:

• Beta-blocker is mandatory unless contraindicated 8
• Treat underlying thyroid disorder

If patient has WPW/pre-excitation:

• Avoid digoxin, beta-blockers, and calcium channel blockers 5, 8
• Refer for accessory pathway ablation 5

The evidence strongly supports that anticoagulation and rate control are the essential discharge medications, while antiarrhythmic drugs should be reserved for patients with documented recurrent symptomatic AF despite adequate rate control 5, 4.